DBV Technologies (NASDAQ:DBVT – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 415.46% from the company’s current price.
Several other equities research analysts also recently issued reports on DBVT. JMP Securities raised their price objective on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research note on Wednesday. StockNews.com began coverage on shares of DBV Technologies in a report on Thursday, July 25th. They set a “hold” rating on the stock.
Get Our Latest Research Report on DBV Technologies
DBV Technologies Price Performance
DBV Technologies (NASDAQ:DBVT – Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative return on equity of 66.96% and a negative net margin of 638.21%. During the same period in the prior year, the firm posted ($0.26) EPS. Analysts anticipate that DBV Technologies will post -1.22 earnings per share for the current year.
Institutional Investors Weigh In On DBV Technologies
A hedge fund recently bought a new stake in DBV Technologies stock. Cowen AND Company LLC purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 50,986 shares of the company’s stock, valued at approximately $49,000. Institutional investors and hedge funds own 71.74% of the company’s stock.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Read More
- Five stocks we like better than DBV Technologies
- EV Stocks and How to Profit from Them
- Procter & Gamble Stock Drops Despite Earnings Beat – What to Know
- Trading Halts Explained
- Financial Sector Shines as Key Players Continue to Beat Earnings
- How to Use the MarketBeat Stock Screener
- Russell 2000 Index Bull Run: This ETF is Poised for Growth
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.